18 February 2019 - Neurolixis launches NLX-112 drug formulation collaboration with GALA® laboratory in France

Neurolixis launched a collaboration with the GALA® laboratory in Castres, France. GALA® is a platform of the Rapsodee/IMT Mines Albi research facility specialized in galenic formulation. GALA® has experimental tools and skills in process engineering, formulation and advanced galenics (encapsulation, vectorization, development of innovative galenic forms).

The Neurolixis-GALA collaboration focuses on the development of a novel formulation of NLX-112. This compound is in clinical development for treatment of dyskinesia (abnormal movements) seen in patients suffering from Parkinson's disease. The new formulation of NLX-112 will optimize its anti-dyskinetic activity and facilitate its administration to patients. The development of NLX-112 has been supported by grants from the Michael J. Fox Foundation, (USA) and Parkinson's UK. The Neurolixis-GALA collaboration is financed by subsidies from the Occitanie Region in France.

Adrian Newman-Tancredi, PhD, DSc, Chief Scientific Officer of Neurolixis, commented: "The development of a novel galenic formulation of NLX-112 will be strong asset for the project and enable Parkinson’s disease patients (about 1 million in the USA) to maximally benefit from this innovative treatment.”

8 February 2019 - Neurolixis and Jagiellonian University publish novel 'biased agonist' antidepressants

Neurolixis and scientists at Jagiellonian University (Krakow, Poland) have published results from a drug discovery program aiming to identify compounds with rapid and efficacious antidepressant activity. The novel serotonin 5-HT1A receptor 'biased agonists' (patent application WO/2017/220799) activate a cellular response associated with antidepressant activity (phosphorylation of ERK enzyme), rather than other signaling pathways. 

Adrian Newman-Tancredi (CSO of Neurolixis) commented: "Depression constitutes a major healthcare challenge because current antidepressants have multiple activities, are only partially efficacious and take weeks to work. We are excited to have identified highly-selective compounds targeting a signaling pathway associated with rapid antidepressant activity. This opens the way for development of a new generation of drugs offering improved and rapid therapy of depressive disorders.”

Novel aryloxyethyl derivatives of 1-(1-benzoylpiperidin-4-yl)methanamine as the Extracellular Regulated Kinases 1/2 (ERK1/2) phosphorylation-preferring serotonin 5‑HT1A receptor biased agonists with robust antidepressant-like activity.
Sniecikowska J, Głuch-Lutwin M, Bucki A, Więckowska A, Siwek A, Jastrzębska-Więsek M, Partyka A, Wilczyńska D, Pytka K, Pociecha K, Cios A, Wyska E, Wesołowska A, Pawłowski MH, Varney M, Newman-Tancredi A, Kołaczkowski M.
Journal Medicinal Chemistry 2019 Feb 5. doi: 10.1021/acs.jmedchem.9b00062. PMID: 30721053